Medscape is available in 5 Language Editions – Choose your Edition here.


Artificial Urinary Sphincter Placement

  • Author: Kamran P Sajadi, MD; Chief Editor: Edward David Kim, MD, FACS  more...
Updated: May 16, 2016


A biological urinary sphincter prevents urinary flow via mucosal coaptation, compression, and pressure transmission. An artificial urinary sphincter (AUS) mimics the biological urinary sphincter by providing a competent bladder outlet during urinary storage and an open unobstructed outlet to permit voluntary voiding.

An artificial urinary sphincter is the only device that closely simulates the function of a biological urinary sphincter. Decades of advances in mechanical design, applications of new technology, and lessons learned from clinical experience have inspired notable improvements.

Novel and ingenious in technical design, the AMS 800 (American Medical Systems, Minnetonka, Minn) device has restored the quality of life to thousands of patients plagued by severe stress urinary incontinence. The AMS 800 prosthesis is the most effective, reliable, and durable surgical treatment for men with postprostatectomy urinary incontinence, achieving social continence rates of 75-95%.

For additional information, see the Medscape article Urinary Incontinence Relevant Anatomy. For supplementary information on urinary incontinence in general, see Medscape’s Urinary Incontinence and OAB Resource Center.


History of the Procedure

Artificial devices to control incontinence are not new. Foley described an artificial sphincter in 1947 that was an externally worn urethral cuff attached to a pump kept in the patient's pocket. The first artificial urinary sphincter to resemble the current model was developed by Dr. Brantley Scott in 1972. Called the AS 721, it consisted of a fluid reservoir, an inflation pump, a deflation pump, and an inflatable cuff with 4 unidirectional valves. The fluid within the sphincter components conveyed the hydraulic pressure to the cuff. Unfortunately, it was mechanically unreliable and carried high urethral erosion rates.

In 1974, a newer model (AS 761) emerged. This model offered a pressure-regulating balloon that allowed automatic cuff closure. This pressure-regulating balloon provided constant predetermined pressure within the hydraulic system, so that the pressure-volume relationship became very predictable.

The AS 761 device was quickly modified into the AS 742 model. This newer sphincter eliminated the need for an inflation pump. The pressure-regulating balloon functioned as a reservoir for cuff fluid. A delay-fill resistor allowed enough time for the patient to void to completion before the urethral cuff closed. However, this prosthesis still was not ideal for patient use.

Introduced in 1979, the AS 791/792 device featured a control assembly that merged the valves and the resistor into a single unit. Surgical implantation was easier, with fewer components and fewer connections. However, the control pump did not have on-off capability. The risk of urethral atrophy and cuff erosion remained high. A second operation was required for activation of this device.

Through continued evolution and improvement, the AMS 800 device was introduced in 1983. During the modification process, the control assembly (valves and resistor) was moved into the pump chamber. This model featured a new locking mechanism that allowed the cuff to remain in either the open or the closed position; thus, the cuff could be left in a deflated (open) state after implantation and could be activated 6-8 weeks later without the need for a second operation.

In 1987, AMS introduced a narrow-backed cuff. This modification improved transmission of pressure to the underlying urethra or bladder neck, which has been proven to decrease the risk of erosion and tissue atrophy. In 1988, the kink-resistant and color-coded tubing was introduced.

The AMS 800 is the most widely used and successful artificial urinary sphincter available. To date, over 94,000 men worldwide have been treated with an AMS 800.



An artificial urinary sphincter is reserved for treatment of complex or severe stress urinary incontinence. Type III stress urinary incontinence, or intrinsic sphincteric dysfunction, is the inability of the urethra to maintain effective resting urethral closure pressure sufficient to keep the patient clinically dry at rest and during periods of reasonable physical activity.



Patients with intrinsic sphincteric dysfunction include men who have undergone radical retropubic prostatectomy (including laparoscopic or robotic-assisted radical prostatectomy), radical perineal prostatectomy, or transurethral resection of the prostate (TURP); patients with previous pelvic trauma or a history of pelvic radiation; and women in whom anti-incontinence procedures have failed. Patients with spinal cord injuries, myelomeningoceles, or other causes of neurogenic bladder may also have intrinsic sphincter dysfunction.



The normal voiding cycle requires that the urinary bladder and the sphincter work as a coordinated unit. The urinary bladder has two functions: it relaxes to store urine (storage or filling phase), and it contracts to eliminate urine (voiding phase). During urinary storage, the bladder is placid and acts as a low-pressure reservoir. During voiding, the bladder actively contracts to act as a pump. The urinary sphincter has two functions: it contracts to store urine and it relaxes to eliminate urine. During urinary storage, the urinary sphincter remains closed to prevent urine loss. At the beginning of the voiding phase, the urinary sphincter opens to allow unobstructed urination.

Urinary incontinence results from dysfunction of the bladder, the sphincter, or a combination of both. Bladder overactivity causes urinary frequency, urgency, and urgency incontinence. Bladder underactivity causes urinary retention. Sphincteric overactivity causes urinary retention. An inadequate or hypoactive sphincter results in stress incontinence. A combination of bladder overactivity and sphincteric underactivity results in mixed urinary incontinence—stress and urge.

Intrinsic sphincteric dysfunction is a complex form of stress incontinence whereby the urethra always remains open. Risk factors for intrinsic sphincteric dysfunction in men include radical prostatectomy, TURP, previous bladder neck surgeries, pelvic radiation, pelvic trauma, and neurologic disorders.

A common denominator of intrinsic sphincteric dysfunction is low urethral resistance at rest and during periods of physical activity. Whenever the intravesical pressure becomes greater than the urethral resistance, stress incontinence ensues. A reliable method of restoring continence is by artificially increasing the urethral resistance. Many approaches to this problem have been devised over the years. The main criterion for implanting an artificial urinary sphincter is a relatively normal detrusor in a setting of intrinsic sphincteric dysfunction.



Patients with intrinsic sphincteric dysfunction present with the classic history of stress urinary incontinence. They experience predictable loss of urine whenever the intravesical pressure exceeds that of the urethral pressure (eg, when coughing, laughing, sneezing, sitting down, or performing the Valsalva maneuver).

Often, patients with intrinsic sphincteric dysfunction complain of involuntary urine loss when changing their body position (eg, when rising from a sitting position). Women with intrinsic sphincteric dysfunction experience more urine loss and require thicker pads than women with incontinence due to urethral hypermobility.

Intrinsic sphincteric dysfunction can often be distinguished from other causes of incontinence by patient history and physical examination. In patients with pure intrinsic sphincteric dysfunction, symptoms of urinary frequency, urgency, and nocturia are typically absent. However, when such storage symptoms are present, coexisting overactive bladder should be suspected. As such, patients should undergo preoperative endoscopic and urodynamic evaluations (see Workup).



Candidates for artificial urinary sphincter include patients with bothersome stress urinary incontinence due to ISD. Indications in men and women of all ages include the following:

  • Postprostatectomy incontinence, which is the most common indication for placement of an artificial urinary sphincter. Placement of the artificial urinary sphincter should be deferred for at least 6 months after prostatectomy; many physicians defer placement for up to 1 year because patients often regain some or all continence during this time.
  • Intrinsic sphincteric dysfunction following pelvic fracture, spinal cord injury, urethral reconstruction, or multiple previous failed anti-incontinence procedures.
  • Neurogenic bladder with associated sphincter or bladder neck incompetence.
  • Although not commonly done in the United States, in Europe the artificial urinary sphincter has been used in women with stress incontinence due to intrinsic sphincter deficiency. This is done through an abdominal, not perineal or vaginal, approach. Long-term data now support this indication, with low rates of mechanical problems and high success rate.

Careful patient selection is arguably the most important factor in predicting success of the artificial urinary sphincter, and the following should be considered:

  • Female patients and children require bladder neck placement of the sphincter and must be motivated to perform and capable of performing clean intermittent catheterization, as this may be required because of postoperative urinary retention.
  • All patients must have sufficient sophistication and hand functionality, as well as manipulative strength, to operate the pump and its associated lock-out mechanism.
  • All patients must understand the potential complications of the operation and the possibility of future surgical interventions for tissue atrophy, cuff erosion, cuff migration, mechanical failure, and device infection. The long-term reoperation rate is about 20%.

Essential characteristics of an ideal patient include highly motivated personality, good manual dexterity, relatively normal detrusor, absence of urinary tract infection (UTI), failure of alternative means of incontinence control, and realistic expectations. Although some patients may expect to remain completely dry, a realistic and satisfactory goal is achieving "social continence", which is generally defined as requiring no more than one incontinence pad a day. Careful patient selection can greatly reduce the likelihood of a disappointed patient and surgeon.

A study by Ziegelmann et al evaluated the impact of patient age on device outcomes among patients undergoing primary artificial urinary sphincter. The study found that although overall artificial urinary sphincter device survival is similar, patients aged >80 years are more likely to experience erosion or infection compared with younger patients. The authors added that despite this, the overall device failure rate is low, and artificial urinary sphincter might be considered for appropriately selected and counseled octogenarians.[1]


Relevant Anatomy

The urethra is composed of an inner epithelial lining, a spongy submucosa with rich vascular plexus, a middle smooth muscle layer, and an outer layer of fibroelastic connective tissue. The spongy submucosa is responsible for providing urethral occlusive pressure. The ability of the urethral mucosa to coapt to generate an adequate urethral closing pressure is an important continence mechanism. Urethral smooth muscle and fibroelastic connective tissues serve to circumferentially augment the occlusive pressure generated by the submucosa.

The urinary sphincter is composed of an internal sphincter and an external sphincter. In females, the internal sphincter is composed of the bladder neck and proximal urethra. In males, the internal sphincter is composed of the bladder neck and prostate. Both males and females possess an external sphincter known as the rhabdosphincter. The rhabdosphincter is omega-shaped and is composed of 2 types of striated muscle fibers—fast twitch and slow twitch. Contraction of fast twitch fibers causes sudden stopping of the urinary stream. This is known as the voluntary guarding reflex. These fibers are responsible for allowing Kegel exercises. Slow twitch fibers maintain the constant tonus of the external sphincter, which is important in daily physical activities. This is known as the involuntary guarding reflex.

For more information about the relevant anatomy, see Female Urethra Anatomy, Female Urinary Organ Anatomy, Male Urethra Anatomy, and Male Urinary Organ Anatomy.



Contraindications for placement of an artificial urinary sphincter include the following:

  • UTI: All candidates for an artificial urinary sphincter should be screened for UTI preoperatively.
  • Recurrent urethral strictures or diverticula
  • Small bladder capacity or poor compliance (However, some patients with this contraindication are candidates for artificial urinary sphincter with concomitant or preoperative augmentation cystoplasty.)

There are also many relative contraindications, such as the following:

  • Grade 2 or higher vesicoureteral reflux should be corrected before artificial urinary sphincter placement.
  • Recurrent disease (eg, stone disease, bladder or ureteral tumors) that requires retrograde endoscopic instrumentation is a relative contraindication. Such instrumentation can predispose to cuff erosion in patients with an artificial urinary sphincter.
  • Bladder neck contractures (a not uncommon complication of prostate surgery) should be treated first, and cystoscopy or retrograde urethrography should be performed at least 3 months afterward to ensure continued patency of the bladder neck before proceeding with artificial urinary sphincter placement.
  • Uncontrolled detrusor overactivity: In patients with significant mixed incontinence, controversy exists about which should be treated first–the bladder or the outlet. One review of post-prostatectomy patients treated with AUS showed that 29% of patients with preoperative OAB had resolution of their OAB; on the other hand, the de novo OAB rate was 23%. All patients were treated with anticholinergics. [2]
Contributor Information and Disclosures

Kamran P Sajadi, MD Assistant Professor, Urology, Oregon Health & Science University

Kamran P Sajadi, MD is a member of the following medical societies: American Urological Association, Endourological Society, Oregon Medical Association, Western Section of the American Urological Association, American Urogynecologic Society, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction

Disclosure: Nothing to disclose.


Martha K Terris, MD, FACS Professor, Department of Surgery, Section of Urology, Director, Urology Residency Training Program, Medical College of Georgia; Professor, Department of Physician Assistants, Medical College of Georgia School of Allied Health; Chief, Section of Urology, Augusta Veterans Affairs Medical Center

Martha K Terris, MD, FACS is a member of the following medical societies: American Cancer Society, Association of Women Surgeons, American Society of Clinical Oncology, Society of Urology Chairpersons and Program Directors, Society of Women in Urology, Society of Government Service Urologists, American College of Surgeons, American Institute of Ultrasound in Medicine, American Urological Association, New York Academy of Sciences, Society of University Urologists

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Shlomo Raz, MD Professor, Department of Surgery, Division of Urology, University of California, Los Angeles, David Geffen School of Medicine

Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, California Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.

Additional Contributors

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Jong M. Choe, MD, FACS, to the development and writing of this article.

  1. Ziegelmann MJ, Linder BJ, Rivera ME, Viers BR, Rangel LJ, Elliott DS. Outcomes of artificial urinary sphincter placement in octogenarians. Int J Urol. 2016 May. 23 (5):419-23. [Medline].

  2. Lai HH, Boone TB. Implantation of artificial urinary sphincter in patients with post-prostatectomy incontinence, and preoperative overactive bladder and mixed symptoms. J Urol. 2011 Jun. 185(6):2254-9. [Medline].

  3. Rapp DE, Reynolds WS, Lucioni A, Bales GT. Surgical technique using AdVance sling placement in the treatment of post-prostatectomy urinary incontinence. Int Braz J Urol. 2007. 33:231 - 5. [Medline].

  4. Stoffel JT, Barrett DM. The artificial genitourinary sphincter. BJU Int. 2008 Aug 5. 102(5):644-58. [Medline].

  5. Magera JS Jr, Inman BA, Elliott DS. Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement?. J Urol. 2007 Oct. 178(4 Pt 1):1328-32; discussion 1332. [Medline].

  6. Yeung LL, Grewal S, Bullock A, Lai HH, Brandes SB. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol. 2013 Jan. 189(1):136-40. [Medline].

  7. Wilson SK, Delk JR 2nd. Ectopic placement of AMS 800 urinary control system pressure-regulating balloon. Urology. 2005 Jan. 65(1):167-70. [Medline].

  8. Sotelo TM, Westney OL. Outcomes related to placing an artificial urinary sphincter using a single-incision, transverse-scrotal technique in high-risk patients. BJU Int. 2008 May. 101(9):1124-7. [Medline].

  9. Henry GD, Graham SM, Cleves MA, Simmons CJ, Flynn B. Perineal approach for artificial urinary sphincter implantation appears to control male stress incontinence better than the transscrotal approach. J Urol. 2008 Apr. 179(4):1475-9; discussion 1479. [Medline].

  10. Elliott DS, Boone TB. Combined stent and artificial urinary sphincter for management of severe recurrent bladder neck contracture and stress incontinence after prostatectomy: a long-term evaluation. J Urol. 2001 Feb. 165(2):413-5. [Medline].

  11. Yates DR, Phé V, Rouprêt M, Vaessen C, Parra J, Mozer P. Robot-assisted laparoscopic artificial urinary sphincter insertion in men with neurogenic stress urinary incontinence. BJU Int. 2013 Jun. 111(7):1175-9. [Medline].

  12. Bryan DE, Mulcahy JJ, Simmons GR. Salvage procedure for infected noneroded artificial urinary sphincters. J Urol. 2002 Dec. 168(6):2464-6. [Medline].

  13. Elliott DS, Barrett DM, Gohma M, Boone TB. Does nocturnal deactivation of the artificial urinary sphincter lessen the risk of urethral atrophy?. Urology. 2001 Jun. 57(6):1051-4. [Medline].

  14. Kowalczyk JJ, Spicer DL, Mulcahy JJ. Long-term experience with the double-cuff AMS 800 artificial urinary sphincter. Urology. 1996 Jun. 47(6):895-7. [Medline].

  15. O'Connor RC, Lyon MB, Guralnick ML, Bales GT. Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. Urology. 2008 Jan. 71(1):90-3. [Medline].

  16. Margreiter M, Farr A, Sharma V, Schauer I, Klingler HC. Urethral buttressing in patients undergoing artificial urinary sphincter surgery. J Urol. 2013 May. 189(5):1777-81. [Medline].

  17. Diokno AC. Erosions of the artificial urinary sphincter: risk factors, outcomes and management. Nat Clin Pract Urol. 2006 Nov. 3(11):580-1. [Medline].

  18. Magera JS Jr, Elliott DS. Tandem transcorporal artificial urinary sphincter cuff salvage technique: surgical description and results. J Urol. 2007 Mar. 177(3):1015-9; discussion 1019-20. [Medline].

  19. Bates AS, Martin RM, Terry TR. Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy: a meta-analysis. BJU Int. 2015 Oct. 116 (4):623-33. [Medline].

  20. Elliott DS, Barrett DM. Mayo Clinic long-term analysis of the functional durability of the AMS 800 artificial urinary sphincter: a review of 323 cases. J Urol. 1998 Apr. 159(4):1206-8. [Medline].

  21. Thomas K, Venn SN, Mundy AR. Outcome of the artificial urinary sphincter in female patients. J Urol. 2002 Apr. 167(4):1720-2. [Medline].

  22. Costa P, Poinas G, Ben Naoum K, Bouzoubaa K, Wagner L, Soustelle L, et al. Long-Term Results of Artificial Urinary Sphincter for Women with Type III Stress Urinary Incontinence. Eur Urol. 2012 Mar 16. [Medline].

  23. Herndon CD, Rink RC, Shaw MB, Simmons GR, Cain MP, Kaefer M. The Indiana experience with artificial urinary sphincters in children and young adults. J Urol. 2003 Feb. 169(2):650-4; discussion 654. [Medline].

  24. Catti M, Lortat-Jacob S, Morineau M, Lottman H. Artificial urinary sphincter in children -- voiding or emptying? An evaluation of functional results in 44 patients. J Urol. 2008. 180:690 - 3. [Medline].

  25. Barrett DM, Furlow WL. Incontinence, intermittent self-catheterization and the artificial genitourinary sphincter. J Urol. 1984 Aug. 132(2):268-9. [Medline].

  26. Barrett DM, O'Sullivan DC, Malizia AA, Reiman HM, Abell-Aleff PC. Particle shedding and migration from silicone genitourinary prosthetic devices. J Urol. 1991 Aug. 146(2):319-22. [Medline].

  27. Choe JM. Freedom Regained: Female Urinary Incontinence Can Be Overcome. Columbus, Ohio: Anadem Publishing; 1999. 199-201.

  28. Choe JM, Staskin DR. Artificial urinary sphincter: evolution and development. J Long Term Eff Med Implants. 1997. 7(1):75-100. [Medline].

  29. DiMarco DS, Elliott DS. Tandem cuff artificial urinary sphincter as a salvage procedure following failed primary sphincter placement for the treatment of post-prostatectomy incontinence. J Urol. 2003 Oct. 170(4 Pt 1):1252-4. [Medline].

  30. Diokno AC, Hollander JB, Alderson TP. Artificial urinary sphincter for recurrent female urinary incontinence: indications and results. J Urol. 1987 Oct. 138(4):778-80. [Medline].

  31. Fishman IJ, Shabsigh R, Scott FB. Experience with the artificial urinary sphincter model AS800 in 148 patients. J Urol. 1989 Feb. 141(2):307-10. [Medline].

  32. Furlow WL, Barrett DM. Recurrent or persistent urinary incontinence in patients with the artificial urinary sphincter: diagnostic considerations and management. J Urol. 1985 May. 133(5):792-5. [Medline].

  33. Goldwasser B, Furlow WL, Barrett DM. The model AS 800 artificial urinary sphincter: Mayo Clinic experience. J Urol. 1987 Apr. 137(4):668-71. [Medline].

  34. Gundian JC, Barrett DM, Parulkar BG. Mayo Clinic experience with use of the AMS800 artificial urinary sphincter for urinary incontinence following radical prostatectomy. J Urol. 1989 Dec. 142(6):1459-61. [Medline].

  35. Heitz M, Olianas R, Schreiter F. [Therapy of female urinary incontinence with the AMS 800 artificial sphincter. Indications, outcome, complications and risk factors]. Urologe A. 1997 Sep. 36(5):426-31. [Medline].

  36. Kreder KJ, Webster GD. Evaluation and management of incontinence after implantation of the artificial urinary sphincter. Urol Clin North Am. 1991 May. 18(2):375-81. [Medline].

  37. Leo ME, Barrett DM. Success of the narrow-backed cuff design of the AMS800 artificial urinary sphincter: analysis of 144 patients. J Urol. 1993 Nov. 150(5 Pt 1):1412-4. [Medline].

  38. Light JK, Reynolds JC. Impact of the new cuff design on reliability of the AS800 artificial urinary sphincter. J Urol. 1992 Mar. 147(3):609-11. [Medline].

  39. Light JK, Scott FB. The artificial urinary sphincter in children. Br J Urol. 1984 Feb. 56(1):54-7. [Medline].

  40. Marques Queimadelos A, Abascal Garcia R, Muruamendiaraz Fernandez V. [Artificial sphincter implantation in women with urinary incontinence using a combined abdomino-vaginal approach]. Arch Esp Urol. 1999 Oct. 52(8):877-80. [Medline].

  41. Martins FE, Boyd SD. Artificial urinary sphincter in patients following major pelvic surgery and/or radiotherapy: are they less favorable candidates?. J Urol. 1995 Apr. 153(4):1188-93. [Medline].

  42. Meulen T, Zambon JV, Janknegt RA. Treatment of anastomotic strictures and urinary incontinence after radical prostatectomy with urolume wallstent and AMS 800 artificial sphincter. J Endourol. 1999 Sep. 13(7):517-20. [Medline].

  43. Montague DK, Angermeier KW. Artificial urinary sphincter troubleshooting. Urology. 2001 Nov. 58(5):779-82. [Medline].

  44. O'Connor RC, Gerber GS, Avila D, Chen AA, Bales GT. Comparison of outcomes after single or DOUBLE-CUFF artificial urinary sphincter insertion. Urology. 2003 Oct. 62(4):723-6. [Medline].

  45. Petero VG Jr, Diokno AC. Comparison of the long-term outcomes between incontinent men and women treated with artificial urinary sphincter. J Urol. 2006 Feb. 175(2):605-9. [Medline].

  46. Raj GV, Peterson AC, Toh KL, Webster GD. Outcomes following revisions and secondary implantation of the artificial urinary sphincter. J Urol. 2005 Apr. 173(4):1242-5. [Medline].

  47. Rose SC, Hansen ME, Webster GD. Artificial urinary sphincters: plain radiography of malfunction and complications. Radiology. 1988 Aug. 168(2):403-8. [Medline].

  48. Saffarian A, Walsh K, Walsh IK, Stone AR. Urethral atrophy after artificial urinary sphincter placement: is cuff downsizing effective?. J Urol. 2003 Feb. 169(2):567-9. [Medline].

  49. Salisz JA, Diokno AC. The management of injuries to the urethra, bladder or vagina encountered during difficult placement of the artificial urinary sphincter in the female patient. J Urol. 1992 Nov. 148(5):1528-30. [Medline].

  50. Scott FB, Bradley WE, Timm GW. Treatment of urinary incontinence by implantable prosthetic sphincter. Urology. 1973 Mar. 1(3):252-9. [Medline].

  51. Shires GT, Canizaro PC. Fluid, Electrolyte, and Nutritional Management of the Surgical Patient. Schwartz SI, Lillehei RC, Shires GT, et al, eds. Principles of Surgery. 2nd ed. New York, NY: McGraw-Hill; 1974. 65.

  52. Smith JJ, Barrett DM. Implantation of the artificial genitourinary sphincter. Walsh PC, ed. Campbell's Urology. 8th ed. Philadelphia, Pa: Elsevier Science; 2002. 1187-94.

  53. Tse V, Stone AR. Incontinence after prostatectomy: the artificial urinary sphincter. BJU Int. 2003 Dec. 92(9):886-9. [Medline].

  54. Webster GD, Guralnick ML. The neurourologic evaluation. Walsh PC, ed. Campbell's Urology. 8th ed. Philadelphia, Pa: Elsevier Science; 2002. 900-30.

  55. Webster GD, Sherman ND. Management of male incontinence following artificial urinary sphincter failure. Curr Opin Urol. 2005 Nov. 15(6):386-90. [Medline].

  56. Webster GD, Sihelnik SA. Troubleshooting the malfunctioning Scott artificial urinary sphincter. J Urol. 1984 Feb. 131(2):269-72. [Medline].

The artificial urinary sphincter (AMS 800) is composed of a pressure-balloon reservoir, an inflate-deflate cuff, and a miniature control pump.
The patient is placed in the dorsolithotomy position. A perineal incision has been made below the scrotum. The Colles fascia is being dissected off.
The bulbocavernosus muscle has been dissected off. The bulbar urethra is exposed.
The right-angle clamp is passed behind the bulbar urethra.
The measuring tape is passed around the bulbar urethra. The bulbar urethra measures 4.5 cm; thus, a 4.5-cm cuff is chosen for implantation.
The artificial urinary sphincter cuff is passed—the tab end first—around the urethra. The cuff is snapped into place.
The tab of the artificial urinary sphincter cuff is rotated dorsally.
The cuff is seated in an excellent position. The tubing from the cuff is passed up to the suprapubic wound, where it is connected to the control pump.
The perineal incision is being closed. The Colles fascia is closed. The skin is closed next.
The balloon reservoir has been placed into the subrectus space, and the control pump has been inserted into the right hemiscrotum because the patient is right-handed. The cuff, pump, and reservoir are all connected.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.